Table 5.

LS mean differences in the change from baseline on the overall DLQI score with omalizumab vs. placebo (95% CI) at Week 12 in ASTERIA I, ASTERIA II and GLACIAL (pooled) and Week 24 in ASTERIA I and GLACIAL (pooled) for patients with and without baseline angioedema

	Patients with angioedema at baseline				Patients without angioedema at baseline
	N a	n b	Treatment difference in LS mean (95% CI)	P‐value	N a	n b	Treatment difference in LS mean (95% CI)	P‐value
ASTERIA I, ASTERIA II and GLACIAL (pooled)—12 weeks
PBO	115	87			127	108
OMA 75 mg	66	50	−1.15 (−3.33 to 1.03)	0.2991	93	84	−1.09 (−2.76 to 0.58)	0.1982
OMA 150 mg	76	55	−1.87 (−3.83 to 0.10)	0.0627	86	78	−2.47 (−4.19 to −0.75)	0.0052
OMA 300 mg	203	169	−4.49 (−5.92 to −3.06)	<0.0001	209	192	−3.57 (−4.76 to −2.38)	<0.0001
ASTERIA I and GLACIAL (pooled)—24 weeks
PBO	85	47			78	60
OMA 75 mg	35	23	2.41 (−1.20 to 6.03)	0.1868	42	36	−1.78 (−3.89 to 0.32)	0.0962
OMA 150 mg	38	22	−0.35 (−3.83 to 3.13)	0.8427	42	33	−1.32 (−3.36 to 0.71)	0.1999
OMA 300 mg	171	133	−3.32 (−5.27 to −1.36)	0.001	162	136	−2.64 (−3.98 to −1.29)	0.0001

^aNumber of patients with or without baseline angioedema.

^bNumber of patients with data at Week 12 or Week 24.

CI, confidence interval; DLQI, Dermatology Life Quality Index; LS, least squares; OMA, omalizumab; PBO, placebo. Modified intent‐to‐treat population (all patients with baseline angioedema). The LS mean was estimated using ancova model with baseline overall DLQI score as covariate, and baseline weight (<80 kg vs. ≥80 kg) as strata. P‐value derived from ancova model.